Portal de Periódicos da CAPES

Perioperative Nivolumab in Resectable Lung Cancer

2024; Massachusetts Medical Society; Volume: 390; Issue: 19 Linguagem: Inglês

10.1056/nejmoa2311926

1533-4406

Tina Cascone, Mark M. Awad, Jonathan Spicer, Jie He, Shun Lü, Boris Sepesi, Fumihiro Tanaka, Janis M. Taube, Robin Cornelissen, Libor Havel, Nina Karaseva, Jarosław Kużdżał, Luboš Petruželka, Lin Wu, Jean-Louis Pujol, Hiroyuki Ito, Tudor‐Eliade Ciuleanu, Ludmila de Oliveira Muniz Koch, Annelies Janssens, Aurelia Alexandru, Sabine Bohnet, Fedor V. Moiseyenko, Yang Gao, Yasutaka Watanabe, Cinthya Coronado Erdmann, Padma Sathyanarayana, S. Meadows–Shropshire, Steven I. Blum, Mariano Provencio,

Lung Cancer Treatments and Mutations

Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadjuvant therapy followed by surgery and adjuvant therapy) with nivolumab may further improve clinical outcomes.